UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting Polo-like Kinase in Cancer Therapy

Clinical cancer research, 2010-01, Vol.16 (2), p.384-389

2010

Volltextzugriff (PDF)

Molecular Target Class Is Predictive of In vitro Response Profile

Cancer research (Chicago, Ill.), 2010-05, Vol.70 (9), p.3677-3686

2010

Volltextzugriff (PDF)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Oncotarget, 2013-12, Vol.4 (12), p.2419-2429

2013

Volltextzugriff (PDF)

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2011-05, Vol.17 (10), p.3420-3430

2011

Volltextzugriff (PDF)

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.720-729

2012

Volltextzugriff (PDF)

Critical role for Daxx in regulating Mdm2

Nature cell biology, 2006-08, Vol.8 (8), p.855-862

2006

Volltextzugriff (PDF)

Metastatic Properties and Genomic Amplification of the Tyrosine Kinase Gene ACK1

Proceedings of the National Academy of Sciences - PNAS, 2005-11, Vol.102 (44), p.15901-15906

2005

Volltextzugriff (PDF)

Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition

International journal of cancer, 2013-02, Vol.132 (3), p.E149-E157

2013

Volltextzugriff (PDF)

Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT034-CT034

2016

Volltextzugriff (PDF)

Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain

Clinical & experimental metastasis, 2011-12, Vol.28 (8), p.899-908

2011

Volltextzugriff (PDF)

Interaction of Zyxin, a Focal Adhesion Protein, with the E6 Protein from Human Papillomavirus Type 6 Results in Its Nuclear Translocation

Journal of Virology, 2001-12, Vol.75 (23), p.11791-11802

2001

Volltextzugriff (PDF)

Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)

Oncotarget, 2011-12, Vol.2 (12), p.1254-1264

2011

Volltextzugriff (PDF)

Gps2, a Protein Partner for Human Papillomavirus E6 Proteins

Journal of Virology, 2001-01, Vol.75 (1), p.151-160

2001

Volltextzugriff (PDF)

High-content analysis of cancer genome DNA alterations

Current opinion in genetics & development, 2008-02, Vol.18 (1), p.68-72

2008

Volltextzugriff (PDF)

High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916

Journal of translational medicine, 2011-07, Vol.9 (1), p.110-110, Article 110

2011

Volltextzugriff (PDF)

Abstract 525: Higher mutation rate is associated with more frequent expression of cancertestis antigens in human tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.525-525

2016

Volltextzugriff (PDF)

Abstract 525: Higher mutation rate is associated with more frequent expression of cancer/testis antigens in human tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.525-525

2016

Volltextzugriff (PDF)

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome

Genes chromosomes & cancer, 2011-08, Vol.50 (8), p.606-618

2011

Volltextzugriff (PDF)

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability

Molecular cancer therapeutics, 2010-07, Vol.9 (7), p.2079-2089

2010

Volltextzugriff (PDF)

Abstract 6268: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.6268-6268

2022

Volltextzugriff (PDF)

Distinct MHC gene expression patterns during progression of melanoma

Genes chromosomes & cancer, 2010-02, Vol.49 (2), p.144-154

2010

Volltextzugriff (PDF)

Abstract 4709: Broad activity for the combination of BET and MEK inhibitors across solid and hematologic cancers

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4709-4709

2016

Volltextzugriff (PDF)

Abstract 382: Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.382-382

2014

Volltextzugriff (PDF)

Abstract 2867: Inhibition of BET bromodomain proteins as a therapeutic approach in small cell lung cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2867-2867

2015

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(74)
Dissertationen
(1)

Sprache

Englisch
(75)
Japanisch
(9)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting Polo-like Kinase in Cancer Therapy

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Molecular Target Class Is Predictive of In vitro Response Profile

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212

Critical role for Daxx in regulating Mdm2

Metastatic Properties and Genomic Amplification of the Tyrosine Kinase Gene ACK1

Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition

Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies

Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain

Interaction of Zyxin, a Focal Adhesion Protein, with the E6 Protein from Human Papillomavirus Type 6 Results in Its Nuclear Translocation

Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)

Gps2, a Protein Partner for Human Papillomavirus E6 Proteins

High-content analysis of cancer genome DNA alterations

High chromosome number in hematological cancer cell lines is a negative predictor of response to the inhibition of Aurora B and C by GSK1070916

Abstract 525: Higher mutation rate is associated with more frequent expression of cancertestis antigens in human tumors

Abstract 525: Higher mutation rate is associated with more frequent expression of cancer/testis antigens in human tumors

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability

Abstract 6268: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy

Distinct MHC gene expression patterns during progression of melanoma

Abstract 4709: Broad activity for the combination of BET and MEK inhibitors across solid and hematologic cancers

Abstract 382: Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Abstract 2867: Inhibition of BET bromodomain proteins as a therapeutic approach in small cell lung cancer

Suchergebnisse filtern